Drugs / Ixabepilone
Ixabepilone
also known as
BMS-247550 · NSC #710428 · Ixempra · NSC 710428D · Azaepothilone b · BMS 247550-01 · Ixabepilona · Ixempra (Ixabepilone) · +2 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | IXEMPRA KIT | — | 2009-10-02 – 2011-10-18 | fda.gov ↗ |
| Approved | US (FDA) | IXEMPRA KIT | — | 2007-10-16 | fda.gov ↗ |
Trials 106 · started per year
today
US approved 2007
1
3
13
10
7
6
6
6
6
17
16
7
3
1
2
1
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 129 trials | ||||||
| Phase 1 | NCT01375829 | Jun 2011 → Jun 2018 overdue | neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01454479 | Mar 2011 → Apr 2013 | endometrial cancer | Hung-Hsueh Chou | Unknown | No outcome recorded |
| Phase 1 | NCT01084057 | May 2010 → Nov 2012 | male breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01012362 | Dec 2009 → Feb 2013 | breast cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma +4 | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT00804310 | Aug 2009 → Aug 2011 | cancer of unknown primary site | University of California, Davis | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00832117 | May 2009 → Jan 2011 | non-small cell lung carcinoma | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00798252 | Mar 2009 → May 2015 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00884676 | Nov 2008 → Nov 2013 | cancer of unknown primary site | Jaime Merchan | Completed | No outcome recorded |
| Phase 1 | NCT00717704 | Jul 2008 → May 2011 | cancer | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00634088 | Jun 2008 → Jun 2010 | breast cancer | R-Pharm | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00632424 | May 2008 → Jun 2009 | cancer | R-Pharm | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00568022 | Feb 2008 → Jan 2010 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00422097 | Jan 2007 → Aug 2009 | cancer | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00322374 | Aug 2006 → Feb 2009 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00362830 | Aug 2006 → Sep 2007 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00207090 | Sep 2005 → Nov 2008 | neoplasm | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00162136 | Sep 2005 → Jul 2008 | cancer | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00207129 | Oct 2004 → Dec 2005 | neoplasm | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT01018966 | Apr 2004 → Mar 2005 | cancer | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00049400 | Oct 2003 → Sep 2006 | lymphoma, small intestine cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 1 | NCT00096317 | Mar 2003 → Dec 2005 | cancer of unknown primary site | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00049244 | Sep 2002 → ? | breast cancer | R-Pharm | Unknown | No outcome recorded |
| Phase 1 | NCT00030108 | Nov 2001 → Mar 2010 | central nervous system neoplasm, childhood germ cell tumor, childhood malignant neoplasm, extragonadal germ cell tumor +6 | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00028561 | Oct 2001 → Feb 2007 | cancer of unknown primary site | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00006221 | Nov 2000 → Jun 2005 | lymphoma, small intestine cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00020371 | Sep 2000 → ? | cancer of unknown primary site, neutropenia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005807 | Jul 2000 → Aug 2004 | breast cancer, ovarian cancer | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00004927 | Jul 1999 → Oct 2002 | cancer of unknown primary site | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT01170871 | — | cancer | University of Southern California | Withdrawn | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT01079793 | May 2010 → Oct 2011 | prostate cancer | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00924352 | Jun 2009 → Oct 2013 | breast cancer | Accelerated Community Oncology Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT00825734 | Mar 2009 → Jun 2013 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00765765 | Feb 2009 → Dec 2011 | breast cancer | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00331344 | Apr 2006 → Nov 2010 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00182767 | Jan 2006 → Apr 2012 | fallopian tube cancer, female breast carcinoma, ovarian carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00045708 | Oct 2002 → May 2010 | anaplastic astrocytoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00057850 | Jan 2002 → Jul 2003 | head and neck cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00025194 | Jul 2001 → Jul 2006 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 262 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT04796324 | Mar 2021 → Dec 2024 | breast cancer | Allarity Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT03093155 | Apr 2017 → Dec 2022 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Yale University | Completed | Met primary |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01818999 | Aug 2013 → Apr 2015 | breast cancer | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01446016 | Sep 2011 → Mar 2019 | breast cancer | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01220609 | Nov 2010 → Jul 2014 | leiomyosarcoma of the corpus uteri | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT01168232 | Sep 2010 → Nov 2013 | carcinosarcoma of the corpus uteri, uterine corpus sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01156753 | Jul 2010 → Oct 2012 | breast cancer | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01057212 | Feb 2010 → Dec 2013 | non-small cell lung carcinoma | Providence Health & Services | Terminated | No outcome recorded |
| Phase 2 | NCT01075100 | Jan 2010 → Jun 2013 | breast cancer | US Oncology Research | Completed | No outcome recorded |
| Phase 2 | NCT00983801 | Nov 2009 → Jun 2011 | gastric cancer | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00977574 | Sep 2009 → Jan 2015 overdue | endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00998101 | Jul → Nov 2009 | lung cancer | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00866905 | Apr 2009 → Jul 2014 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00877500 | Mar 2009 → Dec 2026 expected | Her2-receptor negative breast cancer, bilateral breast carcinoma, invasive breast carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00828308 | Feb 2009 → Mar 2011 | prostate cancer | Brown University | Completed | No outcome recorded |
| Phase 2 | NCT00821886 | Feb 2009 → Jul 2011 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00923130 | Jan 2009 → Mar 2016 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00723957 | Dec 2008 → May 2010 | non-small cell lung carcinoma | R-Pharm | Completed | Missed primary |
| Phase 2 | NCT00924066 | Nov 2008 → Dec 2013 | cervical adenosquamous carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00790894 | Nov 2008 → Apr 2011 | breast cancer | Hellenic Cooperative Oncology Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01097642 | Oct 2008 → Dec 2019 | breast cancer | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00751868 | Sep 2008 → Jul 2011 | breast cancer | Consorzio Oncotech | Completed | No outcome recorded |
| Phase 2 | NCT00741988 | Sep 2008 → Sep 2010 | non-small cell lung carcinoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00633464 | Jun 2008 → Sep 2010 | triple-negative breast carcinoma | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00672009 | Apr 2008 → Apr 2011 | adenocarcinoma, male reproductive system neoplasm, prostate neoplasm, urinary system neoplasm | Cedars-Sinai Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00490646 | Feb 2008 → Jun 2011 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00546364 | Feb 2008 → Mar 2010 | breast cancer | R-Pharm | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00627978 | Nov 2007 → Jan 2011 | breast cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT00455533 | Oct 2007 → Dec 2009 | breast cancer | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 2 | NCT00370552 | Mar 2007 → Nov 2009 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00383149 | Jan 2007 → Jun 2009 | malignant pancreatic neoplasm | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT01027208 | Dec 2006 → Jan 2007 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00331643 | Apr 2006 → Oct 2007 | Ewing sarcoma/peripheral primitive neuroectodermal tumor, alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, kidney cancer +3 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01019577 | Oct 2005 → Jul 2007 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00182702 | Jul 2005 → Sep 2007 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00095979 | May 2005 → Jul 2009 | endometrium adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00077376 | Mar 2005 → Mar 2009 | HER2 positive breast carcinoma, male breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00030706 | Nov 2004 → Feb 2007 | ovarian cancer, peritoneum cancer | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00087139 | Sep 2004 → Apr 2009 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00080262 | Feb 2004 → Dec 2006 | breast cancer, metastatic neoplasm | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00079326 | Jan 2004 → Jul 2008 | HER2 positive breast carcinoma, female breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00070096 | Aug 2003 → Jun 2007 | central nervous system neoplasm, extragonadal germ cell tumor, ovarian cancer, testicular germ cell tumor | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00058084 | Mar 2003 → Oct 2007 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00058019 | Feb 2003 → Aug 2010 | Burkitt lymphoma, anaplastic large cell lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00033618 | Nov 2002 → Jan 2007 | hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, metastatic squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +4 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00052572 | Oct 2002 → Jul 2007 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00025155 | Jul 2002 → Mar 2010 | malignant epithelial tumor of ovary, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00045097 | May 2002 → Jul 2007 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00033306 | Feb 2002 → Jul 2005 | colorectal cancer | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 2 | NCT00030992 | Feb 2002 → Jan 2009 | renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00036764 | Feb 2002 → Aug 2004 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00022477 | Sep 2001 → Oct 2002 | colorectal cancer | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00023946 | Aug 2001 → Jul 2005 | adult hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00016965 | Jul 2001 → Apr 2006 | pancreatic adenocarcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00021099 | Jun 2001 → Aug 2007 | bladder transitional cell carcinoma, renal pelvis/ureter urothelial carcinoma, urethra cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00022542 | Jun 2001 → Jun 2006 | soft tissue sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00016393 | Jun 2001 → Apr 2006 | prostate cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00017056 | Feb 2001 → Jan 2002 | esophageal cancer, gastric cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00017043 | Feb 2001 → Jan 2003 | esophageal cancer, gastric cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00035516 | Feb 2001 → Apr 2004 | non-small cell lung carcinoma | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00020904 | Feb 2001 → Jan 2003 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 36 trials · 1 met primary · 3 missed | ||||||
| Phase 3 | NCT00883116 | Aug 2009 → Jun 2012 | endometrial cancer | R-Pharm | Terminated | Missed primary |
| Phase 3 | NCT00789581 | Dec 2008 → Dec 2015 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00785291 | Oct 2008 → Dec 2013 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer, estrogen-receptor negative breast cancer, estrogen-receptor positive breast cancer +2 | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT00630032 | Sep 2007 → Jun 2017 | breast cancer | UNICANCER | Completed | Missed primary |
| Phase 3 | NCT00082433 | Nov 2003 → Mar 2008 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT00080301 | Sep 2003 → Nov 2006 | breast cancer, metastatic neoplasm | R-Pharm | Completed | Met primary |
| Comparator or background therapy12 trials | ||||||
| Phase 1 | NCT00683904 Comparator | Jun 2008 → Sep 2009 | non-small cell lung carcinoma | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00637897 Background | Mar 2008 → Nov 2011 | breast cancer | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00043095 Background | Jun 2002 → ? | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01349088 Background | Dec 2013 → Sep 2015 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00309049 Comparator | Apr 2006 → May 2007 | cancer | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT02067416 Comparator | Jul 2012 → Jun 2014 | breast cancer | Jenny C. Chang, MD | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01416389 Comparator | Aug 2011 → Aug 2012 | breast cancer | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT00879086 Comparator | Mar 2009 → Apr 2013 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00593827 Comparator | May 2008 → Aug 2010 | breast cancer | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT02915744 Comparator | Nov 2016 → Jul 2020 | breast cancer, metastatic neoplasm | Nektar Therapeutics | Completed | Missed primary |
| Phase 3 | NCT01492101 Comparator | Dec 2011 → Apr 2016 | female breast carcinoma | Nektar Therapeutics | Completed | Missed primary |
| Phase 3 | NCT00998738 Background | Nov 2009 → Jul 2010 | breast carcinoma, peripheral neuropathy | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-07-05 | Allarity Therapeutics | Results Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients allarity.com ↗
Among the evaluable patients assessed up to the data evaluation cut-off, there were promising signs of clinical benefit in four out of four evaluable cases: |
| 2008-12-13 | Bristol-Myers Squibb | Results New Data Demonstrate Significant Improvement in Progression-Free Survival for Triple Negative Metastatic Breast Cancer Patients Treated with IXEMPRA™ Plus Capecitabine bms.com ↗
data show that IXEMPRA plus capecitabine (n = 191 patients) is the first combination regimen to demonstrate statistically significant (p < 0.0001) PFS |
All press releases naming this drug 6 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 125 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ixabepilone | “Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗112“One of the following Treatment of Physician Choice will be administered per standard of care: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel” NCT01492101 ↗ “A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.” PMID 20179242 ↗ Feb 2010 “physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care” NCT02067416 ↗ “Ixabepilone is a semisynthetic analog of the natural product epothilone B” NCT01454479 ↗ “Irinotecan, Ixabepilone, Lapatinib” NCT02788201 ↗ “Ixabepilone 40 mg/m2” NCT00789581 ↗ |
| Known as | Azaepothilone b | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201752 ↗ |
| Known as | BMS 247550-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201752 ↗ |
| Known as | BMS-247550 | “The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.” NCT00207129 ↗12“Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias” NCT00030108 ↗ “Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.” PMID 16314632 ↗ Dec 2005 “A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.” PMID 16699973 ↗ Nov 2006 “Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.” PMID 17261851 ↗ Jan 2007 “Ixabepilone [BMS-247550] will be administered on Day 1 (D1) every three weeks as a 3-hour infusion at a dose of 40 mg/m2.” NCT00790894 ↗ “A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders” NCT00052572 ↗ “Epothilone Analog BMS-247550” NCT00035516 ↗ |
| Known as | Ixabepilona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201752 ↗ |
| Known as | Ixempra | “A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.” PMID 20179242 ↗ Feb 20102“A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer” NCT00924066 ↗ “A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra)” NCT01454479 ↗ |
| Known as | Ixempra (Ixabepilone) | “Ixempra (Ixabepilone)” NCT00825734 ↗ |
| Known as | Ixempra kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201752 ↗ |
| Known as | NSC #710428 | “A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology...” PMID 25091619 ↗ Aug 20144“Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias” NCT00030108 ↗ “A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.” PMID 16699973 ↗ Nov 2006 “A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.” PMID 20179242 ↗ Feb 2010 “A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer” NCT00924066 ↗ |
| Known as | NSC 710428D | “A Phase II Study Of Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Advanced Colorectal Carcinoma” NCT00022477 ↗1“Epothilone B Analogue BMS-247550 (NSC 710428D)” NCT00049400 ↗ |
| Known as | NSC-747973 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201752 ↗ |
| Action | Inhibit | “Ixabepilone is a tubulin-inhibiting agent with low susceptibility to multiple resistance mechanisms including β3T isoform expression in several tumor models.” PMID 23589560 ↗ Apr 2013 |
| Modality | Small molecule | “novel epothilone analog ixabepilone” PMID 17261851 ↗ Jan 2007 |
| Route | Intravenous | “Part I: Patients with advanced solid tumors receive BMS-247550 IV over 1 hour every 3 weeks.” NCT00005807 ↗ |